Truist Securities Reiterates Buy on BeOne Medicines, Raises Price Target to $413

Benzinga Newsdesk www.benzinga.com Positive 83.3%

Neg 0% Neu 0% Pos 83.3%

Truist Securities analyst Gregory Renza reiterates BeOne Medicines (NASDAQ:ONC) with a Buy and raises the price target from $411 to $413.